In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates

Dae Hun Kim; Byung Woo Jhun; Seong Mi Moon; Su Young Kim; Kyeongman Jeon; O. Jung Kwon; Hee Jae Huh; Nam Yong Lee; Sung Jae Shin; Charles L. Daley; Won Jung Koh

doi:10.1128/AAC.00665-19

In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates

Dae Hun Kim, Byung Woo Jhun, Seong Mi Moon, Su Young Kim, Kyeongman Jeon, O. Jung Kwon, Hee Jae Huh, Nam Yong Lee, Sung Jae Shin, Charles L. Daley, Won Jung Koh

Department of Microbiology

Research output: Contribution to journal › Article › peer-review

36 Citations (Scopus)

Abstract

We evaluated the in vitro activities of the antimicrobial drugs bedaquiline and delamanid against the major pathogenic nontuberculous mycobacteria (NTM). Delamanid showed high MIC values for all NTM except Mycobacterium kansasii. However, bedaquiline showed low MIC values for the major pathogenic NTM, including Mycobacterium avium complex, Mycobacterium abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. kansasii. Bedaquiline also had low MIC values with macrolide-resistant NTM strains and warrants further investigation as a potential antibiotic for NTM treatment.

Original language	English
Article number	e00665-19
Journal	Antimicrobial agents and chemotherapy
Volume	63
Issue number	8
DOIs	https://doi.org/10.1128/AAC.00665-19
Publication status	Published - 2019

Bibliographical note

Funding Information:
This research was supported by the National Research Foundation of Korea (NRF), funded by the South Korean Ministry of Science, Information, and Communications Technologies (grant NRF-2018R1A2A1A05018309 to W.-J.K.), and by the Basic Science Research Program through the NRF, funded by the Ministry of Education (grant NRF-2016R1A6A3A11930738 to D.H.K.).

Funding Information:
This research was supported by the National Research Foundation of Korea (NRF), funded by the South Korean Ministry of Science, Information, and Communications Technologies (grant NRF-2018R1A2A1A05018309 to W.-J.K.), and by the Basic Science Research Program through the NRF, funded by the Ministry of Education (grant NRF-2016R1A6A3A11930738 to D.H.K.). C.L.D. has received grants from Insmed, Inc., and served on advisory boards for Otsuka, Insmed, Johnson and Johnson, Spero, and Horizon, not associated with the submitted work. W.-J.K. has received a consultation fee from Insmed, Inc., for the Insmed advisory board meeting, not associated with the submitted work. Otherwise, we have no conflicts of interest to declare.

Publisher Copyright:
Copyright © 2019 American Society for Microbiology. All Rights Reserved.

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/AAC.00665-19

Cite this

Kim, D. H., Jhun, B. W., Moon, S. M., Kim, S. Y., Jeon, K., Kwon, O. J., Huh, H. J., Lee, N. Y., Shin, S. J., Daley, C. L., & Koh, W. J. (2019). In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates. Antimicrobial agents and chemotherapy, 63(8), Article e00665-19. https://doi.org/10.1128/AAC.00665-19

@article{840a0299706844409bd51fb6081d520c,

title = "In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates",

abstract = "We evaluated the in vitro activities of the antimicrobial drugs bedaquiline and delamanid against the major pathogenic nontuberculous mycobacteria (NTM). Delamanid showed high MIC values for all NTM except Mycobacterium kansasii. However, bedaquiline showed low MIC values for the major pathogenic NTM, including Mycobacterium avium complex, Mycobacterium abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. kansasii. Bedaquiline also had low MIC values with macrolide-resistant NTM strains and warrants further investigation as a potential antibiotic for NTM treatment.",

author = "Kim, {Dae Hun} and Jhun, {Byung Woo} and Moon, {Seong Mi} and Kim, {Su Young} and Kyeongman Jeon and Kwon, {O. Jung} and Huh, {Hee Jae} and Lee, {Nam Yong} and Shin, {Sung Jae} and Daley, {Charles L.} and Koh, {Won Jung}",

note = "Funding Information: This research was supported by the National Research Foundation of Korea (NRF), funded by the South Korean Ministry of Science, Information, and Communications Technologies (grant NRF-2018R1A2A1A05018309 to W.-J.K.), and by the Basic Science Research Program through the NRF, funded by the Ministry of Education (grant NRF-2016R1A6A3A11930738 to D.H.K.). Funding Information: This research was supported by the National Research Foundation of Korea (NRF), funded by the South Korean Ministry of Science, Information, and Communications Technologies (grant NRF-2018R1A2A1A05018309 to W.-J.K.), and by the Basic Science Research Program through the NRF, funded by the Ministry of Education (grant NRF-2016R1A6A3A11930738 to D.H.K.). C.L.D. has received grants from Insmed, Inc., and served on advisory boards for Otsuka, Insmed, Johnson and Johnson, Spero, and Horizon, not associated with the submitted work. W.-J.K. has received a consultation fee from Insmed, Inc., for the Insmed advisory board meeting, not associated with the submitted work. Otherwise, we have no conflicts of interest to declare. Publisher Copyright: Copyright {\textcopyright} 2019 American Society for Microbiology. All Rights Reserved.",

year = "2019",

doi = "10.1128/AAC.00665-19",

language = "English",

volume = "63",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates

AU - Kim, Dae Hun

AU - Jhun, Byung Woo

AU - Moon, Seong Mi

AU - Kim, Su Young

AU - Jeon, Kyeongman

AU - Kwon, O. Jung

AU - Huh, Hee Jae

AU - Lee, Nam Yong

AU - Shin, Sung Jae

AU - Daley, Charles L.

AU - Koh, Won Jung

N1 - Funding Information: This research was supported by the National Research Foundation of Korea (NRF), funded by the South Korean Ministry of Science, Information, and Communications Technologies (grant NRF-2018R1A2A1A05018309 to W.-J.K.), and by the Basic Science Research Program through the NRF, funded by the Ministry of Education (grant NRF-2016R1A6A3A11930738 to D.H.K.). Funding Information: This research was supported by the National Research Foundation of Korea (NRF), funded by the South Korean Ministry of Science, Information, and Communications Technologies (grant NRF-2018R1A2A1A05018309 to W.-J.K.), and by the Basic Science Research Program through the NRF, funded by the Ministry of Education (grant NRF-2016R1A6A3A11930738 to D.H.K.). C.L.D. has received grants from Insmed, Inc., and served on advisory boards for Otsuka, Insmed, Johnson and Johnson, Spero, and Horizon, not associated with the submitted work. W.-J.K. has received a consultation fee from Insmed, Inc., for the Insmed advisory board meeting, not associated with the submitted work. Otherwise, we have no conflicts of interest to declare. Publisher Copyright: Copyright © 2019 American Society for Microbiology. All Rights Reserved.

PY - 2019

Y1 - 2019

N2 - We evaluated the in vitro activities of the antimicrobial drugs bedaquiline and delamanid against the major pathogenic nontuberculous mycobacteria (NTM). Delamanid showed high MIC values for all NTM except Mycobacterium kansasii. However, bedaquiline showed low MIC values for the major pathogenic NTM, including Mycobacterium avium complex, Mycobacterium abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. kansasii. Bedaquiline also had low MIC values with macrolide-resistant NTM strains and warrants further investigation as a potential antibiotic for NTM treatment.

AB - We evaluated the in vitro activities of the antimicrobial drugs bedaquiline and delamanid against the major pathogenic nontuberculous mycobacteria (NTM). Delamanid showed high MIC values for all NTM except Mycobacterium kansasii. However, bedaquiline showed low MIC values for the major pathogenic NTM, including Mycobacterium avium complex, Mycobacterium abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. kansasii. Bedaquiline also had low MIC values with macrolide-resistant NTM strains and warrants further investigation as a potential antibiotic for NTM treatment.

UR - http://www.scopus.com/inward/record.url?scp=85070660434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070660434&partnerID=8YFLogxK

U2 - 10.1128/AAC.00665-19

DO - 10.1128/AAC.00665-19

M3 - Article

C2 - 31182533

AN - SCOPUS:85070660434

SN - 0066-4804

VL - 63

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 8

M1 - e00665-19

ER -

In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this